INM inmedpharma.com: Forward P/S Multiple

Official company branding of InMed (INM)

InMed Pharmaceuticals focuses on the biosynthesis of rare cannabinoids, where success depends on FDA approval. High barriers to entry are created by unique patents and strict government oversight. The brand's scientific prestige is confirmed by physician trust. The expected P/S metric visualizes the dynamics of market forecasts, with the indicator fixed at 104.30, which helps assess the risks of a future asset revaluation.

INM (InMed Pharmaceuticals Inc.) Forward Price to Sales history from 07/04/2022 to 11/09/2026

Comprehensive metric breakdowns and analytics for InMed (INM)

- current price and projected stock value:
Stock Price InMed Pharmaceuticals Inc.|INM - Average Forecast Price
- company stock capitalization data:
Market Capitalization InMed|INM - Business Value
- issuer book value statistics:
Accounting Value per Share InMed Pharmaceuticals|INM - Accounting Value of Company|Market Value to Book Value Ratio inmedpharma.com|INM - Total Asset Value of Company
- company total debt and liquidity indicators:
Total Debt to Capital InMed Pharmaceuticals|INM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital InMed Pharmaceuticals|INM - Company Aggregate Debts|Debt to Book Capitalization Ratio InMed|INM - Company Long-Term Loans and Borrowings|Company Short-Term Debt InMed Pharmaceuticals|Quick Ratio inmedpharma.com
- net income and valuation multiples indicators:
INM - Net Profit|Projected Future Earnings InMed Pharmaceuticals|INM - Price to Earnings Ratio|Forward P/E Multiple InMed Pharma|INM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio InMed|INM - Operating profit EBITDA|Net earnings per share for the last 12 months InMed Pharmaceuticals|INM - Earnings per share for the last four quarters|Quarterly EPS earnings growth inmedpharma.com|INM - Expected net earnings per share growth this year|Earnings growth forecast for next year InMed Pharmaceuticals
- company sales and revenue statistics:
INM - Company Sales|Projected Sales Volume InMed Pharmaceuticals Inc.|INM - P/S Multiple|Price-to-Projected Revenue Ratio InMed
Fundamental company analysis:INM (InMed Pharmaceuticals Inc.)
Product sample of InMed

To protect capital from volatility, it is essential for investors to understand how market value correlates with projected earnings. The current value of 104.30 in the expected P/S ratio reflects the demand balance for InMed Pharmaceuticals (INM) shares, where unique genetic engineering patents and strict FDA oversight mitigate risks, allowing the amplitude of this metric to be used for precisely determining portfolio entry points.

Key competitors

Forward P/S Multiple INDV (Indivior)|Collegium Pharma (COLL) - Market Cap to Future Revenue Ratio|Cronos - Forward P/S Multiple|CGC (Canopy Growth Corp.) - Market Cap to Projected Revenue|HITI (High Tide Inc.) - Forward Price-to-Revenue Multiple|Aurora Cannabis Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Achieve Life Sciences, Inc.|Skye Bioscience Inc. - Future Price to Revenue|Forward P/S Multiple ANEB|INCR (intercure.co) - Forward Price to Sales|Forward P/S Multiple NTRB (Nutriband)|Forward P/S Multiple Nasus Pharma Ltd. NSRX|IGC - Price-to-Projected Revenue Ratio|Forward Price to Sales MIRA (MIRA Pharmaceuticals)|Flora Growth Corporation (FLGC) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple IM Cannabis|ADIL (Adial Pharmaceuticals Inc.) - Forward P/S Multiple|Forward P/S Multiple Artelo|Forward P/S Multiple ENSC|Forward Price-to-Revenue Multiple titanpharm.com TTNP|Forward P/S Multiple GNLN (Greenlane Holdings Inc)|Akanda Inc (AKAN) - Market Cap to Future Revenue Ratio|ENVB: Forward Price-to-Revenue Multiple|BGXX - Forward P/S Multiple|HPCO (Hempacco Co., Inc.) - Forward Price-to-Revenue Multiple